Statement of Principles concerning malignant neoplasm of the brain (Reasonable Hypothesis) (No. 17 of 2026)

This instrument, the Statement of Principles concerning malignant neoplasm of the brain (Reasonable Hypothesis) (No. 17 of 2026), repeals and replaces the previous 2016 version (No. 85 of 2016). It is a legislative instrument made under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (VEA). Its sole function is to specify the minimum factors that must exist before a reasonable hypothesis can be raised connecting malignant neoplasm of the brain, or death from that disease, with the circumstances of a person’s relevant service as defined in the VEA or the Military Rehabilitation and Compensation Act 2004 (MRCA). Mechanically, once this instrument commences on 23 March 2026, any claim to which section 120A of the VEA or section 338 of the MRCA applies must be assessed against these factors. If none of the listed factors exists and is reasonably related to the person’s service, a decision‑maker cannot find that a reasonable hypothesis exists, which in turn prevents the claim from succeeding under the lower standard of proof applicable to operational, peacekeeping, hazardous and similar service. The instrument therefore sharply constrains the range of medical evidence that can be used to support a compensation claim. It does not create new rights or obligations directly but operates as a binding evidentiary gatekeeper. The instrument also sets out the meaning of malignant neoplasm of the brain for its own purposes, which is narrower than the ICD‑10‑AM code C71 might suggest because it expressly excludes several tumour types such as meningioma, lymphoma and pituitary adenoma. It includes a note that the RMA determined the factors on the basis of sound medical‑scientific evidence, but that claim is an opinion expressed by the instrument’s maker rather than a conclusion that a court or tribunal must accept. Practitioners need to be aware that the instrument effectively raises the evidentiary bar for claimants whose disease may have environmental or occupational causes not captured by the five specified factors.

The instrument defines several key concepts. Malignant neoplasm of the brain means a primary malignant neoplasm arising from the cells of the brain, including malignant neuroepithelial tumour and germ cell tumour, but expressly excludes nerve sheath tumour, soft tissue sarcoma, central nervous system lymphoma (Hodgkin’s or non‑Hodgkin’s), carcinoid tumour, neoplasm of the pituitary gland, cerebral meningioma, acoustic neuroma, choroid plexus papilloma, craniopharyngioma, dysembryoplastic neuroepithelial tumour, gangliocytoma, hemangioblastoma, hemangiopericytoma, meningioma, neurofibroma, pituitary adenoma, schwannoma and soft tissue sarcoma of the brain. The term neuroepithelial tumour is defined in the dictionary with a non‑exhaustive list including choroid plexus tumours, diffuse astrocytic and oligodendroglial tumours, embryonal tumours, ependymal tumours, neuronal and mixed neuronal‑glial tumours, other astrocytic tumours, other gliomas and tumours of the pineal region. Cumulative equivalent dose means the total dose of ionising radiation to a particular organ or tissue from external exposure, internal exposure or both, excluding normal background radiation in Australia, calculated according to the ARPANSA guide as in force on 2 August 2017. The instrument gives examples of exposure scenarios: being present during nuclear weapons testing or use, undergoing diagnostic or therapeutic medical procedures involving ionising radiation, and being an aircrew member subject to increased cosmic radiation. For dose reconstruction, dose is averaged over the mass of the specific tissue or organ.

Benzene exposure is quantified as a cumulative exposure greater than 500 ppm‑years accumulated over a continuous 5‑year period, with first exposure at least 5 years before clinical onset. The note explains that ppm‑years means parts per million multiplied by years of exposure. Moderate to severe traumatic brain injury is not further defined in the instrument; its interpretation will rely on clinical guidelines and possibly on other Statements of Principles if such a condition has its own SoP. Parkinson’s disease is likewise not defined here, but if an SoP exists for that disease, the factors of that SoP will apply by force of section 11. Inability to obtain appropriate clinical management is a factor that applies only to material contribution or aggravation of the disease where the disease was suffered or contracted before or during (but did not arise out of) relevant service. The instrument also introduces the concept of , defined non‑exhaustively as pneumonia, respiratory failure, cardiac arrest, circulatory failure or cessation of brain function. is defined by reference to the VEA and MRCA categories: operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA.

The instrument directly affects three main groups. First, it affects veterans and members who have rendered relevant service as defined in the dictionary: operational, peacekeeping, hazardous or British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA. These individuals, or their surviving dependents, must satisfy at least one of the five factors to raise a reasonable hypothesis linking their brain cancer to that service. Second, it affects decision‑makers at the Department of Veterans’ Affairs and the Military Rehabilitation and Compensation Commission, who are bound by the instrument when assessing claims. They cannot accept a hypothesis that relies on a factor not listed in section 9, unless that factor is incorporated by reference through another SoP under section 11. Third, it affects medical and scientific experts who provide evidence in support of or against a claim. They must be able to quantify factors such as cumulative equivalent dose of ionising radiation to the brain (requiring dosimetry) or benzene exposure over a continuous five‑year period (requiring exposure reconstruction). For the traumatic brain injury factor, experts must confirm that the injury was moderate to severe and occurred at least five years before clinical onset. Claimants themselves bear the practical burden of obtaining this evidence, which can be costly and time‑consuming. The instrument does not directly affect private enterprise or commercial activity, but it imposes indirect compliance costs: veterans may need to engage private medical specialists, occupational hygienists or dosimetrists, and these costs may not be recoverable even if the claim succeeds. The instrument also has an allocative effect: it channels compensation only to those cases that fit the five factors, potentially excluding claimants with brain cancers from causes that are not yet supported by “sound medical‑scientific evidence” as assessed by the RMA. Taxpayers bear the ultimate cost of successful claims through the consolidated revenue fund.

The instrument itself imposes no duties directly on any person; it is an evidentiary standard. However, it creates a framework in which rights and duties arise under the VEA and MRCA. Claimants have the right to have their claim assessed by reference to this instrument if it applies. They also have the right to present evidence that at least one factor exists and is related to their relevant service. Conversely, the duty of the decision‑maker is to apply the instrument strictly: if none of the factors in section 9 is satisfied, the decision‑maker must find that no reasonable hypothesis exists, and the claim must be determined under the “reasonable satisfaction” standard, which is more difficult for the claimant. Where a factor refers to an injury or disease that itself is the subject of a Statement of Principles (for example, Parkinson’s disease or traumatic brain injury, if they have their own SoPs), the factors of that other SoP apply by force of section 11. This creates a cascading duty: the decision‑maker must examine, not only the direct factor in this SoP, but also whether the factors of the referenced SoP are satisfied. The factor concerning “inability to obtain appropriate clinical management” comes with its own limitation under section 10(2): it applies only to material contribution to, or aggravation of, the disease where the disease was already suffered or contracted before or during (but did not arise out of) relevant service. This restricts its operation to cases where the disease pre‑existed service and was made worse by a lack of clinical management due to service circumstances. Claimants have no right to have a hypothesis considered if it is not consistent with the factors in this instrument; the instrument therefore limits the freedom of claimants to advance medical theories not endorsed by the RMA. There is no right to appeal the instrument itself, but its application in a particular claim may be reviewed by the Administrative Appeals Tribunal or the Federal Court on grounds of legal error or jurisdictional fact.

This instrument does not create any criminal penalties, civil penalties or enforcement mechanisms of its own. It operates as a legislative instrument that defines a standard of proof for compensation claims. The only “enforcement” occurs through the adjudication of those claims. If a decision‑maker fails to apply the instrument correctly - for example, by accepting a hypothesis that does not include any of the listed factors, or by misinterpreting a factor - the resulting decision may be set aside on review. The Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004 provide for internal review and external merits review by the Administrative Appeals Tribunal, and judicial review by the Federal Court. There is no penalty imposed on a claimant for making a false claim, but if a claimant knowingly presents false evidence about a factor (such as fabricating a traumatic brain injury or falsifying benzene exposure records), they may be prosecuted under general criminal law provisions for fraud or giving false information. The instrument itself does not address this; it simply sets the evidentiary threshold. The Repatriation Medical Authority, which made the instrument, is not subject to penalty for any alleged error in the factors, although its determination can be challenged on grounds that it failed to consider sound medical‑scientific evidence (a ground of ultra vires under the VEA). In practice, the enforcement of the instrument is passive: it is the framework within which claims succeed or fail. The most significant consequence for a claimant is the denial of compensation if they cannot fit within the factors. The instrument does not impose any reporting obligations, record‑keeping requirements or compliance costs on businesses or individuals beyond those necessary to gather evidence for a claim.

The instrument is made under subsection 196B(2) of the Veterans’ Entitlements Act 1986 and must be read together with that Act, particularly section 120A, which provides that a reasonable hypothesis must be consistent with the relevant Statement of Principles. It also applies to claims under section 338 of the Military Rehabilitation and Compensation Act 2004, which incorporates the same standard for warlike and non‑warlike service. The instrument interacts with other Statements of Principles through section 11: if a factor refers to an injury or disease for which an SoP has been determined under subsection 196B(2) of the VEA, then the factors of that other SoP apply as in force from time to time. For example, if Parkinson’s disease has its own Reasonable Hypothesis SoP, the decision‑maker must determine whether that SoP’s factors are satisfied before the Parkinson’s disease factor in this brain cancer SoP can be used. This creates a complex layered analysis. The instrument explicitly references ICD‑10‑AM code C71 but states that the meaning of malignant neoplasm of the brain for the purposes of the SoP is that given in subsection 7(2), which is narrower. This means that a diagnosis that attracts code C71 in a medical record may still fall outside the SoP’s definition if it is one of the excluded tumour types (e.g., meningioma). Such a diagnosis would require a different SoP if one exists for that tumour type. The instrument also interacts with the Repatriation Medical Authority’s own Guide to calculation of ‘cumulative equivalent dose’, which is incorporated by reference as in force on 2 August 2017. Any future amendment to that guide would not automatically affect this SoP unless the SoP is itself amended. The instrument does not affect or override the general provisions of the VEA or MRCA concerning service eligibility, claim procedures, or rates of pension. It sits within Part XIA of the VEA, which establishes the system of Statements of Principles. The repeal of the 2016 SoP means that claims made after commencement must be determined under this instrument, even if the disease was diagnosed or the claim was lodged earlier.

The instrument states that it repeals the Statement of Principles concerning malignant neoplasm of the brain (Reasonable Hypothesis) (No. 85 of 2016) (Federal Register of Legislation No. F2016L01692) made under subsection 196B(2) of the VEA. That is the only amendment history provided in the source. The new instrument is designated No. 17 of 2026, dated 20 February 2026, and commences on 23 March 2026. The instrument recites that the Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence justifying the factors. This is a statement of the basis for making the instrument under section 196B(2). The previous 2016 SoP has been completely replaced; all its factors are superseded. Because the source does not reproduce the 2016 SoP, we cannot identify which factors were added, removed or modified in the 2026 version. However, the existence of a new instrument after nine years suggests that the RMA reviewed the medical literature and may have changed the factors accordingly. Notably, the instrument includes factors for benzene exposure and for inability to obtain appropriate clinical management. Whether these were present in the 2016 version is unknown from this source. Practitioners should not assume continuity; the current instrument must be applied in its own terms. The repeal of the 2016 SoP means that any previous case law interpreting the old factors may be of limited value unless the wording of the factors is identical. The instrument does not contain a transitional provision; it applies to claims made on or after commencement. There is no grandfathering for claims lodged before 23 March 2026 but not yet determined; the VEA and MRCA have their own transitional rules, but the instrument itself is silent. The amendment history is therefore limited to a single repeal event. The instrument also notes the authority under which it is made and sets out the standard‑form definitions.

The source contains no reference to any litigation history concerning this specific instrument or its predecessor. No cases are named. The instrument is a legislative determination by the RMA, and as such it is not itself a court decision. However, Statements of Principles are frequently challenged in the Administrative Appeals Tribunal and the Federal Court, often on grounds that the RMA erred in deciding that there is not sound medical‑scientific evidence for a particular factor, or that the factor as expressed is ambiguous or ultra vires. Because this instrument is new, any litigation arising from it will occur after commencement. The previous 2016 SoP may have been the subject of judicial review, but that is not mentioned in the source. In the absence of litigation history in the source, an analyst can note that the instrument establishes a framework that will inevitably be litigated. For example, the definition of cumulative equivalent dose incorporates a specific ARPANSA guide as in force on 2 August 2017, and parties may dispute whether a particular dose reconstruction methodology complies with that guide. Similarly, the benzene exposure factor requires calculation over a continuous five‑year period; the meaning of “continuous” may be contested where exposure was intermittent. The traumatic brain injury factor requires the injury to be moderate to severe; the classification of severity (e.g., Glasgow Coma Scale, post‑traumatic amnesia) could be challenged. The factor for inability to obtain appropriate clinical management is unusual and may generate litigation about what constitutes “appropriate” management and whether the claimant took reasonable steps to obtain it. None of this is recorded in the instrument, but it is foreseeable. For the purpose of this deep dive, the present litigation history is nil according to the source. The instrument’s application in practice will create the first tranche of cases.

Several points in the instrument can trap the unwary. The definition of malignant neoplasm of the brain is narrower than the ICD‑10‑AM code C71 suggests. A person may have a brain tumour that is clinically malignant and coded C71, but if it is a lymphoma, meningioma, pituitary adenoma, acoustic neuroma, schwannoma or several other listed exclusions, it falls outside this SoP. Claimants with such tumours must find a different SoP (if one exists for that specific tumour type) or rely on the general “reasonable satisfaction” standard, which is much harder to satisfy. Moderate to severe traumatic brain injury is not defined in the instrument. No diagnostic criteria, Glasgow Coma Scale scores, or imaging findings are given. This leaves room for dispute and will likely require expert evidence. The same ambiguity applies to “Parkinson’s disease” - the term is used but not defined; a claimant must also satisfy the factors of any SoP for Parkinson’s disease under section 11, effectively creating a double evidentiary hurdle. The benzene exposure factor requires “a cumulative exposure to benzene greater than 500 ppm‑years, where that exposure was accumulated over a continuous 5-year period”. The 500 ppm‑years threshold is extremely high. For context, an exposure of 100 ppm for five continuous years would meet the threshold, but occupational exposure standards in Australia are much lower (typically 1 ppm over an 8‑hour day). The factor likely requires exposure in exceptional circumstances, such as working with pure benzene in unregulated environments. The “continuous 5‑year period” language is also problematic: gaps in exposure may break continuity. The instrument does not define what constitutes a break. The ionising radiation factor requires a cumulative equivalent dose of at least 0.1 sievert to the brain, excluding normal background radiation. That is roughly equivalent to 10 CT scans of the head or several years of aircrew cosmic radiation. Claimants must calculate dose using the ARPANSA guide as in force on 2 August 2017, not any later version. A change in that guide after that date is not incorporated. The factor regarding inability to obtain appropriate clinical management only applies to material contribution or aggravation where the disease existed before or during service (section 10(2)). It cannot be used to establish initial onset. Moreover, if appropriate clinical management was unavailable due to service circumstances, the claimant must prove that the lack of management actually worsened the outcome. This is a difficult evidentiary burden. Finally, the instrument provides that . This means that if a claimant relies on traumatic brain injury, they may need to satisfy the traumatic brain injury SoP factors - which may themselves be stringent. The same applies to Parkinson’s disease. This creates a chain of causation that can break at any link.

Compliance with this instrument is not about following rules; it is about using it to advance or defeat a compensation claim. For a claimant or their representative, the first step is to confirm that the diagnosis falls within the instrument’s definition of malignant neoplasm of the brain. Excluded tumours (meningioma, lymphoma, pituitary adenoma, etc.) cannot be pursued under this SoP. If the diagnosis is covered, the representative must identify which factor(s) can be supported by evidence and relate them to the person’s relevant service. For moderate to severe traumatic brain injury, obtain contemporaneous medical records (emergency department notes, hospital discharge summaries, neurology assessments) showing the injury occurred at least five years before the clinical onset of the brain cancer. The injury must be classified as moderate or severe using accepted clinical scales; a mild concussion will not suffice. For Parkinson’s disease, obtain a confirmed diagnosis of Parkinson’s disease made before the brain cancer diagnosis. Then separately assess whether the Parkinson’s disease itself is related to service by reference to the Parkinson’s disease SoP (if one exists). If that SoP’s factors are not satisfied, the factor in this instrument cannot succeed. For ionising radiation, engage a health physicist or radiation dosimetrist to calculate the cumulative equivalent dose to the brain from service‑related exposures (e.g., participation in nuclear tests, occupational exposure as a radiographer, aircrew cosmic radiation). Count only exposures above normal background. The calculation must follow the ARPANSA guide dated 2 August 2017. The dose must be at least 0.1 Sv and the exposure must have occurred at least two years before clinical onset. For benzene exposure, assemble a detailed exposure history covering a continuous five‑year period during service. Obtain workplace monitoring data, job descriptions, and material safety data sheets. Calculate cumulative exposure in ppm‑years (average ppm × years). The total must exceed 500 ppm‑years. This will almost certainly require industrial hygiene expert evidence. The first exposure must be at least five years before the brain cancer diagnosis. For inability to obtain appropriate clinical management, show that the person had malignant neoplasm of the brain before or during service, and that due to service circumstances (e.g., remote deployment, lack of medical facilities, failure to diagnose) appropriate treatment was not received, leading to clinical worsening. This factor does not apply to the initial onset of the disease. Decision‑makers assessing claims must check each factor against the instrument, incorporate any referenced SoPs for underlying conditions, and ensure that the existence of the factor is related to relevant service. The instrument does not specify a standard of proof for establishing the factors; the regular civil standard (balance of probabilities) applies within the reasonable hypothesis framework.